Prostate cancer (PC) is the most common non-cutaneous malignancy in adult males in
|
|
- Eric Atkins
- 5 years ago
- Views:
Transcription
1 A Short Review of Prostate Cancer Molecular Imaging Jaspreet S. Batra, MD, and Simin Dadparvar, MD Background: Prostate cancer (PC) is the most common non-cutaneous malignancy in adult males in the United States and the second most common cause of cancer death in this population. In 2018, it is projected there will be 164,690 new cases of PC and about 29,430 deaths attributable to this disease [1]. Due to aggressive screening with serum total prostate specific antigen (PSA) and routine digital rectal examination, the diagnosis is usually made at an early stage of the disease while still localized to the prostate gland. When localized, it is characterized by a good prognosis, displaying an indolent course. However, PC can be a progressive disease for patients who are categorized as high risk [2] and many times is diagnosed after it has already spread locoregionally or to distant sites. Approximately 6% of new PC cases present with metastatic disease with a 5-yr survival rate of only 29% [3]. For all stages combined, overall survival is 99% [1]. For patients who decide to undergo curative treatment, radical prostatectomy (RP) or radiation therapy (RT), PSA is used as a marker for disease recurrence. According to international consensus, after radical prostatectomy, biochemical recurrence (BCR) of PC may be defined by two consecutive PSA values of >0.2 ng/ml and if rising [4-6]. Following primary radiotherapy, the RTOG-ASTRO Phoenix Consensus Conference definition of PSA failure is any PSA increase >2 ng/ml higher than the PSA nadir value, regardless of the serum concentration of the nadir. Despite all the advances that have been made in primary treatment options and the improvement in the overall survival of prostate cancer, 20-40% of patients experience disease relapse in the form of BCR [7, 8], and it is well
2 known that a rising PSA level can precede metastatic spread [6]. Some of the clinical parameters that determine the likelihood of recurrence or metastasis are PSA doubling time, PSA velocity, Gleason s score, and pathological stage. Currently, the imaging workup for patients with high-risk primary prostate cancer, BCR, or metastatic disease includes conventional imaging modalities 99m Tc-methylenediphosphonate bone scan, CT, and sometimes MRI. However, CIM have a notoriously low sensitivity in detecting lesions when the patient has a low disease volume or low serum total PSA level [9]. Early detection of recurrence or small volume metastatic disease in specific patients, along with new treatment options, can potentially increase the overall survival for these patients [10]. Molecular imaging offers us the ability to identify previously undetectable metastases, which can directly affect the clinical staging and treatment outcomes [11]. Positron emission tomography (PET) imaging is a functional molecular imaging technique and is considered the standard of care for the initial staging and for post-treatment followup to assess treatment response and/or disease progression for many different malignancies. 18 F fluorodeoxyglucose ( 18 F FDG) is the most common radiopharmaceutical used for oncologic PET imaging, although it has a limited role in PC, because PC cells (especially hormone-naïve) have low glycemic activity, which limits the 18 F-FDG uptake. Traditionally, 18 F FDG-PET imaging has been utilized to detect metabolic activity, blood flow, and apoptosis. However, newer PET radiopharmaceuticals have the ability to identify upregulated molecular targets/receptors or novel biological pathways [12].
3 18F NaF (sodium fluoride) is a radiotracer that has a favorable biodistribution as it diffuses into the active bone remodeling sites (both lytic and blastic lesions) by exchanging fluoride ions with hydroxide ions of the hydroxyapatite crystals, forming fluorapatite [13]. Despite its superior diagnostic performance in the detection of bone metastases (compared to 99 Tc bone scan) [14] as well its ability to visualize smaller lesions better, with higher resolution and high target/background ratio, 18 F-NAF-PET/CT is no longer reimbursed by the Centers for Medicare and Medicaid Services (CMS). 18F Fluciclovine PET/CT ( 18F FACBC, Axumin ) Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid ( 18 F-FACBC or fluciclovine) is a synthetic L leucine analog that has high tumor-specific accumulation through amino acid transporters-alanine-serine-cysteine transporter 2 (ASCT2) and large neutral amino acid transporter 1 (LAT1), which are known to be upregulated in PC [15,16]. The FDA approved this radiopharmaceutical in May 2016 for patients with suspected recurrence based on elevated PSA following prior treatment. Biodistribution of fluciclovine is similar to other amino acid based PET radiopharmaceuticals, and the primary sites of uptake include pancreas, liver, bone marrow, salivary glands, lymphoid tissue, and the pituitary gland. There is minimal uptake by the brain and little urinary excretion (in the first 24 hours), which can be advantageous to image cerebrum, retroperitoneal space, and the pelvis [17]. Dosimetry is similar to 18F FDG [18]. Most experience with fluciclovine has been gained in the recurrent PC disease subset. In one study, investigators reported higher sensitivity and specificity for detecting local and
4 extra-prostatic disease in comparison to 11 C-choline [19], in patients radically treated for PC who had developed BCR. A meta-analysis of different PET tracers demonstrated that 18 F-fluciclovine had greater ability to detect locally recurrent disease versus 18 F-choline, although the difference was not statistically significant [20]. Additionally, fluciclovine is easy to produce, has a longer half-life, and has better tumor-to-background activity. CIM for BCR has limited accuracy, especially when the PSA level is low [21]. Multiple trials have now shown that fluciclovine can detect low-volume disease (small lymph nodes, small soft tissue, and bone lesions) otherwise not visualized on CIM but confirmed by histological findings [22]. One of the limitations to optimal use of fluciclovine is increased uptake in non-malignant conditions such as benign prostatic hyperplasia and prostatitis, which may coexist with localized PC disease, thus limiting the interpretation of the images. Representative cases of metastatic PC imaged with fluciclovine radiopharmaceutical:
5 Figure 1. Patient diagnosed with PC. Physiological uptake in the liver is seen and nonspecific uptake in the bone marrow. The fluciclovin-avid left posterior mediastinal lymph node along with a focus of intense uptake in the L1 vertebra are highly suspicious for malignant disease.
6 Figure 2: PC patient imaged with fluciclovine. Physiological uptake is seen in the liver. Moderate-to-intense increased uptake in the bilateral paraaortic retroperitoneal lymph nodes thoracic vertebral body is suspicious for metastatic disease. Mild uptake in the left renal cortex is likely physiological.
7 Gallium-68 ( 68 Ga) PSMA PET/CT Prostate-specific membrane antigen (PSMA) is a type II membrane metalloenzyme. The healthy prostate gland expresses comparatively little PSMA, which is confined within the apical membrane of secretory duct. Unlike PSA, which can be elevated in many benign conditions (like benign prostate hyperplasia, prostatitis, instrumentation), PSMA is upregulated in PC cells ( times more in PC than in benign prostate cells and other tissues), preferentially localizes to the luminal surface of the ducts during the transition to androgen independence, and is most often associated with high-grade disease [23]. PSMA expression increases with increasing tumor stage and grade and in castration-resistant PC. The newer generation 68 Ga-PSMA ligands target the extracellular domain of PSMA, with strong binding affinity, and are internalized into the endosomal recycling system with rapid blood clearance and low background activity. These characteristics lead to high-quality images with high tumor-to-background ratios [24]. 68 Ga-labeled PSMA-HBED-CC is the most common radiopharmaceutical used for PSMA PET/CT imaging. It consists of a urea-based small molecule ligand that is structured to attach to the extracellular domain, significantly increasing sensitivity. Biodistribution of 68 Ga-PSMA-HBED-CC includes uptake in the salivary and lacrimal glands, liver, spleen, kidneys, and intestine [25]. High physiologic liver uptake can be confounding to evaluate for any occult liver metastases. Also, uptake is seen in ganglia as well as minimal uptake in bone marrow (less than 11 C-choline). 68 Ga-labeled PSMA HBED CC is primarily excreted in the urine.
8 In a systemic review and meta-analysis of 16 articles with a total 1,309 patients, for those with BCR, the detection rate by PSMA-based PET/CT imaging increased with an increase in serum PSA levels (42% at PSA <0.2 ng/ml to 95% at PSA >2 ng/ml). Shorter PSA doubling time also increased 68 Ga PSMA-PET positivity. Overall sensitivity and specificity were 86% each on per-patient analysis, and the overall sensitivity and specificity were 80% and 97%, respectively, on per-lesion analysis [26]. 68 Ga-PSMA- PET/CT can be an important diagnostic tool in the setting of initial staging. In a study with 130 patients with intermediate and high-risk patients, 68 Ga PSMA PET/CT outperformed conventional imaging modalities (CT or MRI) in assessing nodal disease assessment [27]. Hepatic uptake (limiting liver metastases evaluation), the investigational nature of 68 Ga- PSMA-HBED-CC, and the requirement for a 68 Ga generator limits its current availability in the US. Other PSMA ligands such as 18 F-DFPyL show promising results. In a small prospective comparative study with 68 Ga-PSMA-HBED-CC in 14 PC patients with BCR, 18 F-DCFPyL detected all the suspicious lesions detected by 68 Ga-PSMA-HBED-CC and additional suspicious lesions in 3 patients, indicating a higher sensitivity for 18F-DCFPyL [28]. Representative cases of metastatic PC imaged with 68 Ga-PSMA-HBED-CC PET/CT
9 Figure 3: 67 year-old male diagnosed with high risk PC. Physiological urine excretion is is seen in the urinary bladder. PSMA-avid left internal iliac node (SUVmax 26.8, measuring 1.3 x 0.9 cm) is seen.
10
11 Figure 4 76-year-old gentleman diagnosed with PC in Status-post hormonal therapy (2013 to 2017) and Enzalutamide (February 2016 to August 2018). Two sets of images from the same patient (March 2018 and August 2018) are displayed for comparison. There is overall interval progression of disease on the later images. New PSMA uptake is seen in several nodes and in the bones. New PSMA-avid para-aortic (SUVmax 19.8, 0.4 cm), left external iliac, perirectal, and presacral nodes are seen. New PSMA uptake is seen in the bilateral humeri and clavicles, manubrium, sternum, bilateral ribs, bilateral scapulae, a few vertebrae, right iliac bone (SUVmax 79.5), left iliac bone, the sacrum, bilateral acetabulae, and bilateral femurs. Interval increased PSMA uptake is seen in L3. Mild grossly stable nonspecific focal PSMA uptake is seen in the lateral aspect of the left 5th rib. Interval more extensive PSMA uptake is seen in the prostate (SUVmax 75.1, previous SUVmax 59.2) and the right seminal vesicle. Acknowledgement Appreciation to Dr. Saabry Osmany for providing the 68 Ga-PSMA images. References: 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, CA: a cancer. J Clin. 2018(1);68: Tombal B: Non metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol, suppl 2012;23:x Howlader N, Noone AM, Krapcho M, et al, editors. SEER Cancer Statistics Review, Freedland SJ, Presti JC Jr, Amling CL et al. Time trends in biochemical recurrence after radical prostatectomy: results of the SEARCH database. Urology. 2003;61(4): Thompson IM, Valicenti RK, Albertsen P et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J. Urol. 2013;190(2): N Dow J, Briganti A, De Santis M et al. European Association of Urology Guidelines Kim, M. M., Hoffman, K. E., Levy, L. B. et al. Improvement in prostate cancer survival over time: a 20-year analysis. Cancer J. 2012;18(1): Bruce, J. Y., Lang, J. M., McNeel, D. G. et al. Current controversies in the management of biochemical failure in prostate cancer. Clin Adv Hematol Oncol. 2012;10(11): Rouvi`ere O. Imaging techniques for local recurrence of prostate cancer: for whom, why and how? Diagn. Interv. Imaging. 2012;93(4): Ost P, Reynders D, Decaestecker K et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5): Mena E, Lindenberg ML, Shih JH et al: Clinical impact of PSMA based 18F DCFBC PET/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. Eur J Nucl Med Mol Imaging 2018; 45: Evans JD, Jethwa KR, Ost P et al: Prostate cancer specific PET radiotracers: a review on the clinical utility in recurrent disease. Pract Radiat Oncol 2018;8(1): Kurdziel KA, Shih JH, Apolo AB et al: The kinetics and reproducibility of 18F-sodium fluoride for oncology using current PET camera technology. J Nucl Med. 2012;53(8): Harmon SA, Perk T, Lin C et al: Quantitative assessment of early 18 F-sodium fluoride positron emission tomography/computed tomography response to treatment in men with metastatic prostate cancer to bone. J Clin Oncol. 2017;35(24): Okudaira H, Shikano N, Nishii R, et al. Putative transport mechanism and intracellular fate of trans 1 amino 3 18F fluorocyclobutanecarboxylic acid in human prostate cancer. J Nucl Med 2011; 52(5): Schuster DM, Votaw JR, Nieh PT et al: Initial experience with the radiotracer anti 1 amino 3 18F fluorocyclobutane 1 carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007; 48(1): Schuster DM, Nanni C, Fanti S, et al. Anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease. J Nucl Med. 2014;55(12): McParland BJ, Wall A, Johansson S, et al. The clinical safety, biodistribution and internal radiation dosimetry of 18 F- fluciclovine in healthy adult volunteers. Eur J Nucl Med Mol Imaging. 2013;40(8):
12 19. Nanni C, Zanoni L, Pultrone C, et al. (18)F FACBC (anti1 amino 3 (18)F fluorocyclobutane 1 carboxylic acid) versus (11)C choline PET/CT in prostate cancer relapse: results of a prospective trial. Eur J Nucl Med Mol Imaging 2016;43(9): Yu CY, Desai B, Ji L et al: Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature. Am J Nucl Med Mol Imaging 2014; 4(6): NCCN: NCCN clinical practice guidelines in oncology: Prostate cancer. Version Andriole GL, Kostakoglu L, Chau A, et al. The Impact of Positron Emission Tomography with 18F-Fluciclovine on the Management of Patients with Biochemical Recurrence of Prostate Cancer: Results from the LOCATE Trial. J Urol. 2018; [Epub ahead of print]. 23. Huang, E, Teh, BS, Mody, DR, et al. Prostate adenocarcinoma presenting with inguinal lymphadenopathy. Urology. 2003;6(2): Wallitt KL, Khan SR, Dubash S, et al. Clinical PET imaging in prostate cancer. RadioGraphics. 2017;37(5): Afshar-Oromieh A, Malcher A, Eder M, et al. PET imaging with a [ 68 Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging. 2013;40(4): Perera M, Papa N, Christidis D, Wetherell D, Hofman MS, Murphy DG, Bolton D, Lawrentschuk N. Sensitivity, specificity, and predictors of positive 68Ga prostate specific membrane antigen positron emission tomography in advanced prostate cancer: a systematic review and meta analysis. European urology Dec 1;70(6): Maurer T, Gschwend JE, Rauscher I, Souvatzoglou M, Haller B, Weirich G, Wester HJ, Heck M, Kübler H, Beer AJ, Schwaiger M. Diagnostic efficacy of 68gallium PSMA positron emission tomography compared to conventional imaging for lymph node staging of 130 consecutive patients with intermediate to high risk prostate cancer. The Journal of urology May 1;195(5): Dietlein M, Kobe C, Kuhnert G et al: Comparison of [ 18 F]DCFPyL and [ 68 Ga]Ga-PSMA-HBED-CC for PSMA-PET imaging in patients with relapsed prostate cancer. Mol Imaging Biol. 2015; 17(4):
Phillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA
ADVANCED PET IMAGING IN PROSTATE CANCER Phillip J. Koo, MD Division Chief of Diagnostic Imaging Banner MD Anderson Cancer Center, USA PET, positron-emission tomography DISCLAIMER Please note: The views
More informationUsing PET/CT in Prostate Cancer
Using PET/CT in Prostate Cancer Legal Disclaimer These materials were prepared in good faith by MITA as a service to the profession and are believed to be reliable based on current scientific literature.
More informationDisease State Overview and Unmet Clinical Need
Disease State Overview and Unmet Clinical Need In 2016 an estimated 180,890 American men will be diagnosed with prostate cancer, making it the most commonly diagnosed non cutaneous neoplasm in men in the
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationFLUCICLOVINE: 1 ST FDA APPROVED F-18 PET IMAGING AGENT FOR RECURRENT PROSTATE CANCER
FLUCICLOVINE: 1 ST FDA APPROVED F-18 PET IMAGING AGENT FOR RECURRENT PROSTATE CANCER KEVIN P BANKS, MD SAN ANTONIO MILITARY MEDICAL CENTER ASSISTANT PROFESSOR OF RADIOLOGY, USU I HAVE NO FINANCIAL DISCLOSURES.
More informationProstate Cancer Basics: Background Information for Outreach Activities with Oncologists, Urologists and Surgeons
Prostate Cancer Basics: Background Information for Outreach Activities with Oncologists, Urologists and Surgeons Legal Disclaimer These materials were prepared in good faith by MITA as a service to the
More informationMolecular Imaging in Prostate Cancer. Carlos Artigas Nuclear Medicine Institut Jules Bordet
Molecular Imaging in Prostate Cancer Carlos Artigas Nuclear Medicine Institut Jules Bordet Introduction 3 different stages of the disease Local treatment with curative intent Introduction 3 different stages
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationPSMA PET SCANNING AND THERANOSTICS IN PROSTATE CANCER KEVIN TRACEY, MD, FRCPC PRECISION DIAGNSOTIC IMAGING REGIONAL PET/CT CENTRE
PSMA PET SCANNING AND THERANOSTICS IN PROSTATE CANCER KEVIN TRACEY, MD, FRCPC PRECISION DIAGNSOTIC IMAGING REGIONAL PET/CT CENTRE DISCLOSURES/CONFLICTS NONE OBJECTIVES Understand current diagnostic role
More informationINDICATIONS AND USAGE
1. INDICATIONS AND USAGE a) Axumin is indicated for positron emission tomography (PET) in men with suspected prostate cancer recurrence based on elevated blood prostate specific antigen (PSA) levels following
More informationRadioligand imaging & treatment of prostate cancer
Radioligand imaging & treatment of prostate cancer Christiaan Schiepers, MD, PhD University of California Los Angeles CANM-CAMRT JOINT ANNUAL CONFERENCE MARCH 22-24, 2018 VANCOUVER, B.C. I do not have
More informationAssessment of Skeletal Metastases in Prostate Cancer: 68Ga-PSMA PET vs 99mTc-MDP WBBS - A Case Series
Assessment of Skeletal Metastases in Prostate Cancer: 68Ga-PSMA PET vs 99mTc-MDP WBBS - A Case Series Poster No.: R-0094 Congress: 2016 ASM Type: Scientific Exhibit Authors: O. Bennett, Y.-T. T. Huang;
More informationστη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου
Η θέση του PET/CT στη σταδιοποίηση του καρκίνου του προστάτη Γ. Αρσος, Γ Εργ. Πυρηνικής Ιατρικής ΑΠΘ, ΓΝΘ Παπαγεωργίου 2014 : the Guidelines year. PRINCIPLES OF IMAGING Imaging is performed for the detection
More informationNuclear Medicine related studies for Prostate cancer
Nuclear Medicine related studies for Prostate cancer ผศ. พญ. ว ชชนา จาร ญร ตน Wichana Chamroonrat, MD 14 กรกฎาคม 2560 เวลา 15:15-15:40น. ณ ห องประช มท านผ หญ ง ช น 5 อาคารศ นย การแพทย ส ร ก ต Courtesy
More information10/30/2018. Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018
Martha K. Terris, MD Witherington Distinguished Professor and Chair Medical College of Georgia Urology November 5, 2018 Elevated PSA and/or nodule on digital rectal examination Prostate biopsies If initial
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationGa 68 -HBED- PSMA. A/ProfLouise Emmett St Vincent s Hospital Sydney
Ga 68 -HBED- PSMA A/ProfLouise Emmett St Vincent s Hospital Sydney Glu-NH-CO-NH-Lys-(Ahx)- [68Ga(HBED-CC)] Prostate specific membrane antigen 35 pub-med publications 15 clinical 3 retrospective larger
More informationNew Concepts in PET Imaging Prostate Cancer
New Concepts in PET Imaging Prostate Cancer Leonard G. Gomella, MD Chairman, Department of Urology Director Sidney Kimmel Cancer Network Sidney Kimmel Cancer Center Thomas Jefferson University Philadelphia,
More informationNovel Imaging in Advanced Prostate Cancer
Novel Imaging in Advanced Prostate Cancer Robert J. Hamilton, MD MPH FRCSC Princess Margaret Cancer Centre ICUC Saturday January 21, 2017 Company/Organizati Details Faculty/Presenter on Disclosures I am
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationManaging Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps?
Managing Prostate Cancer After Initital Treatment Fails: Are There Good Next Steps? Michael J Zelefsky, M.D. Professor of Radiation Oncology Chief Brachytherapy Service Department of Radiation Oncology
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationDoes Imaging of Advanced PC change a suggested treatment?
Does Imaging of Advanced PC change a suggested treatment? Professor Bertrand Tombal, MD, PhD Cliniques universitaires Saint-Luc Université catholique de Louvain Brussels, Belgium Credentials and conflict
More informationShort summary of published results of PET with fluoromethylcholine (18F) in prostate cancer
Short summary of published results of PET with fluoromethylcholine (18F) in prostate cancer JN TALBOT and all the team of Service de Médecine Nucléaire Hôpital Tenon et Université Pierre et Marie Curie,
More informationStaging of Prostatic Carcinoma - The evolving use of SPECT-CT and Positron Emission Tomography (PET)
Staging of Prostatic Carcinoma - The evolving use of SPECT-CT and Positron Emission Tomography (PET) Poster No.: C-2477 Congress: ECR 2015 Type: Educational Exhibit Authors: B. Rawal, N. Vasdev, R. P.
More informationPET/CT imaging and RIT of prostate cancer. Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark
PET/CT imaging and RIT of prostate cancer Kirsten Bouchelouche, MD, DMSc PET & Cyclotron Unit Rigshospitalet, Copenhagen Denmark Prostate cancer Prostate cancer is the most common malignancy in men Imaging
More informationF NaF PET/CT in the Evaluation of Skeletal Malignancy
F NaF PET/CT in the Evaluation of Skeletal Malignancy Andrei Iagaru, MD September 26, 2013 School of of Medicine Ø Introduction Ø F NaF PET/CT in Primary Bone Cancers Ø F NaF PET/CT in Bone Metastases
More informationUpdates in Prostate Cancer Treatment 2018
Updates in Prostate Cancer Treatment 2018 Mountain States Cancer Conference Elaine T. Lam, MD November 3, 2018 Learning Objectives Understand the difference between hormone sensitive and castration resistant
More informationPET in Prostate Cancer
PET in Prostate Cancer Tom R. Miller, M.D., Ph.D. Mallinckrodt Institute of Radiology Washington University School of Medicine St. Louis, Missouri, USA Prostate Imaging Bone Scintigraphy primarily for
More informationPSMA PET in patients with prostate cancer
PSMA PET in patients with prostate cancer Thomas Hope, MD Assistant Professor of Radiology, UCSF Abdominal Imaging and Nuclear Medicine Co-director, PET/MRI Chief of MRI, San Francisco VA Medical Center
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationProf. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C.
Role of Whole-body Diffusion MR in Detection of Metastatic lesions Prof. Dr. NAGUI M. ABDELWAHAB,M.D.; MARYSE Y. AWADALLAH, M.D. AYA M. BASSAM, Ms.C. Cancer is a potentially life-threatening disease,
More informationDr Sneha Shah Tata Memorial Hospital, Mumbai.
Dr Sneha Shah Tata Memorial Hospital, Mumbai. Topics covered Lymphomas including Burkitts Pediatric solid tumors (non CNS) Musculoskeletal Ewings & osteosarcoma. Neuroblastomas Nasopharyngeal carcinomas
More informationThe Use of PET Scanning in Urologic Oncology
The Use of PET Scanning in Urologic Oncology Dr Nicholas C. Buchan Uro-oncology Fellow 1 2 Aims To understand the basic concepts underlying PET scanning. Understand the emerging role of PET Scanning for
More informationElevated PSA. Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017
Elevated PSA Dr.Nesaretnam Barr Kumarakulasinghe Associate Consultant Medical Oncology National University Cancer Institute, Singapore 9 th July 2017 Issues we will cover today.. The measurement of PSA,
More informationFDG PET/CT STAGING OF LUNG CANCER. Dr Shakher Ramdave
FDG PET/CT STAGING OF LUNG CANCER Dr Shakher Ramdave FDG PET/CT STAGING OF LUNG CANCER FDG PET/CT is used in all patients with lung cancer who are considered for curative treatment to exclude occult disease.
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationEvidence of choline PET CT scan for detecting early recurrence or metastatic prostatic cancer
Original article Evidence of choline PET CT scan for detecting early recurrence or metastatic prostatic cancer Sachin Yallappa, Isthiakul Rizvi Glasgow Royal infirmary, Birmingham Queen Elizabeth Hospital,
More informationAN EDUCATIONAL SUPPLEMENT TO. Importance of identifying the early emergence of metastatic disease in prostate cancer
AN EDUCATIONAL SUPPLEMENT TO Importance of identifying the early emergence of metastatic disease in prostate cancer 2 Importance of identifying the early emergence of metastatic disease in prostate cancer
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationLow risk. Objectives. Case-based question 1. Evidence-based utilization of imaging in prostate cancer
Evidence-based utilization of imaging in prostate cancer Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Objectives State the modalities,
More informationLong-term Results of a Comparative PET/CT and PET/MRI Study of 11 C-Acetate and 18 F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer
ORIGINAL ARTICLE Long-term Results of a Comparative PET/CT and PET/MRI Study of 11 C-Acetate and 18 F-Fluorocholine for Restaging of Early Recurrent Prostate Cancer Giorgio Lamanna, MD,* Claire Tabouret-Viaud,
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationFDG-PET/CT in Gynaecologic Cancers
Friday, August 31, 2012 Session 6, 9:00-9:30 FDG-PET/CT in Gynaecologic Cancers (Uterine) cervical cancer Endometrial cancer & Uterine sarcomas Ovarian cancer Little mermaid (Edvard Eriksen 1913) honoring
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationWhole Body MRI. Dr. Nina Tunariu. Prostate Cancer recurrence, progression and restaging
Whole Body MRI Prostate Cancer recurrence, progression and restaging Dr. Nina Tunariu Consultant Radiology Drug Development Unit and Prostate Targeted Therapies Group 12-13 Janeiro 2018 Evolving Treatment
More informationRadioimmunoscintigraphy (Monoclonal Antibody Imaging) With Indium 111 Capromab Pendetide for Prostate Cancer
Last Review Status/Date: December 2016 Page: 1 of 9 Antibody Imaging) With Indium 111 Capromab Description Radioimmunoscintigraphy (RIS) involves the administration of radiolabeled monoclonal antibodies
More informationInterpretation of 11C choline PET/CT for the diagnosis of local relapse in radically treated prostate cancer
Matti et al. European Journal of Hybrid Imaging (2017) 1:5 DOI 10.1186/s41824-017-0007-x European Journal of Hybrid Imaging SHORT COMMUNICATION Open Access Interpretation of 11C choline PET/CT for the
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More informationPRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES
PRECISION IMAGING: QUANTITATIVE, MOLECULAR AND IMAGE-GUIDED TECHNOLOGIES Day 3 Authors: Tade, Funmilayo; Akin-Akintayo Oladunni; Schuster, David M. Lab Training Module 1: Introduction to the basics of
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationWhole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review
Whole body F-18 sodium fluoride PET/CT in the detection of bone metastases in patients with known malignancies: A pictorial review Poster No.: C-1196 Congress: ECR 2014 Type: Educational Exhibit Authors:
More informationProstate Cancer and PSMA:
Prostate Cancer and PSMA: The Clinical Perspective from Liverpool. Dr. Christopher Mayes. Professor Sobhan Vinjamuri. Department of Nuclear Medicine Royal Liverpool University Hospital (BSUR 2016 Plymouth)
More informationPET/CT Value: Rocky Mountain Cancer Centers
PET/CT Value: Rocky Mountain Cancer Centers Glenn Balasky Executive Director Rocky Mountain Cancer Centers glenn.balasky@usoncology.com CANM/CAMRT Joint Conference March 22, 2018 Vancouver, British Columbia
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationL approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo
L approccio alle stazioni linfonodali in presentazione di malattia ed all eventuale recidiva nodale: il punto di vista dell urologo Paolo Gontero Division of Urology Città della Salute e della Scienza
More informationUniversity of Groningen. Morphological aspects of recurrent prostate cancer Rybalov, Maxim
University of Groningen Morphological aspects of recurrent prostate cancer Rybalov, Maxim IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it.
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationThe Utility of Molecular Imaging in Prostate Cancer
Curr Urol Rep (2016) 17: 26 DOI 10.1007/s11934-015-0573-z UROSURGERY (J COLLINS, SECTION EDITOR) The Utility of Molecular Imaging in Prostate Cancer Aaron Leiblich 1 & Daniel Stevens 2 & Prasanna Sooriakumaran
More informationDefinition Prostate cancer
Prostate cancer 61 Definition Prostate cancer is a malignant neoplasm that arises from the prostate gland and the most common form of cancer in men. localized prostate cancer is curable by surgery or radiation
More informationJoelle Hamilton, M.D.
Joelle Hamilton, M.D. www.urologycentersalabama.com Case Presentation: CRPC, Rising PSA 70 yo healthy, fit, active man post RALP 8 years prior with rising PSA Rising PSA from 0.02 nadir to 3.4 thus ADT
More informationControversies in Prostate Cancer Screening
Controversies in Prostate Cancer Screening William J Catalona, MD Northwestern University Chicago Disclosure: Beckman Coulter, a manufacturer of PSA assays, provides research support PSA Screening Recommendations
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
PET Scanning: Oncologic Applications Page 1 of 88 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Positron Emission Tomography (PET) Scanning: Oncologic Applications
More informationGa68 Imaging. Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium
Ga68 Imaging Roland HUSTINX Division of Nuclear Medicine and Oncologic Imaging Centre Hospitalier Universitaire de Liège Belgium 68 Ga Produced by a 68 Ge/ 68 Ga generator Decays by positron emission
More informationNCCN Guidelines for Prostate V Meeting on 06/28/18
Guideline Page and Request PROS-2 through PROS-11 and PROS-D (pages 3 and 4). External request from GenomeDx Biosciences Request the NCCN Prostate Cancer Guidelines Panel to review the data in support
More informationIndex. Surg Oncol Clin N Am 16 (2007) Note: Page numbers of article titles are in boldface type.
Surg Oncol Clin N Am 16 (2007) 465 469 Index Note: Page numbers of article titles are in boldface type. A Adjuvant therapy, preoperative for gastric cancer, staging and, 339 B Breast cancer, metabolic
More informationDiagnostic role of fluorodeoxyglucose positron emission tomography computed tomography in prostate cancer
ONCOLOGY LETTERS 7: 2013-2018, 2014 Diagnostic role of fluorodeoxyglucose positron emission tomography computed tomography in prostate cancer YIYAN LIU Nuclear Medicine Service, Department of Radiology,
More informationNIH Public Access Author Manuscript Diagn Imaging Eur. Author manuscript; available in PMC 2014 November 10.
NIH Public Access Author Manuscript Published in final edited form as: Diagn Imaging Eur. 2013 January ; 29(1): 12 15. PET-directed, 3D Ultrasound-guided prostate biopsy Baowei Fei, Department of Radiology
More informationChallenging Cases. With Q&A Panel
Challenging Cases With Q&A Panel Case Studies Index Patient #1 Jeffrey Wieder, MD Case # 1 72 year old healthy male with mild HTN Early 2011: Preop bone scan and pelvic CT = no mets Radical prostatectomy
More informationperformed to help sway the clinician in what the appropriate diagnosis is, which can substantially alter the treatment of management.
Hello, I am Maura Polansky at the University of Texas MD Anderson Cancer Center. I am a Physician Assistant in the Department of Gastrointestinal Medical Oncology and the Program Director for Physician
More informationOriginal Article Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of literature
Am J Nucl Med 2014;4(6):580-601 www.ajnmmi.us /ISSN:2160-8407/ajnmmi0001396 Original Article Comparative performance of PET tracers in biochemical recurrence of prostate cancer: a critical analysis of
More informationPage 1 of CONTRAINDICATIONS None (4)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXUMIN safely and effectively. See full prescribing information for AXUMIN. AXUMIN (fluciclovine
More informationPSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationX, Y and Z of Prostate Cancer
X, Y and Z of Prostate Cancer Dr Tony Michele Medical Oncologist Prostate cancer Epidemiology Current EUA (et al) guidelines on Advanced Prostate Cancer Current clinical management in specific scenarios
More informationImaging of prostate cancer local recurrences : why and how?
Imaging of prostate cancer local recurrences : why and how? Olivier Rouvière Department of Urinary and Vascular Imaging Hospices Civils de Lyon Lyon - France 1. Preliminary Remarks Preliminary Remarks
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationPET-MRI in malignant bone tumours. Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany
PET-MRI in malignant bone tumours Lars Stegger Department of Nuclear Medicine University Hospital Münster, Germany Content From PET to PET/MRI General considerations Bone metastases Primary bone tumours
More informationAdjuvant and Salvage Radiation for Prostate Cancer. Savita Dandapani, MD, PhD
Adjuvant and Salvage Radiation for Prostate Cancer Savita Dandapani, MD, PhD DISCLOSURES I am a consultant for Reflexion, receive funding from Bayer, and on the Speaker s Bureau with Astra Zeneca. Post-prostatectomy
More informationAssessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose
Assessment of renal cell carcinoma by two PET tracer : dual-time-point C-11 methionine and F-18 fluorodeoxyglucose Poster No.: C-0805 Congress: ECR 2015 Type: Scientific Exhibit Authors: S. Ito, K. Kato,
More informationAccepted Manuscript. S (18) /j.adro Reference: ADRO 244. To appear in: Advances in Radiation Oncology
Accepted Manuscript Percutaneous image guided nodal biopsy after C-11 Choline PET/CT for Biochemically Recurrent Prostate Cancer: Imaging Predictors of Disease and Clinical Implications B.T. Welch, A.T.
More information[PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK
06 March, 2018 [PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK Document Filetype: PDF 506.4 KB 0 [PDF] ALTERNATIVES TO LUPRON FOR PROSTATE CANCER EBOOK See information on benefits and safety. We
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationAmerican College of Radiology ACR Appropriateness Criteria Post-treatment Follow-up of Prostate Cancer
Revised 2017 American College of Radiology ACR Appropriateness Criteria Post-treatment Follow-up of Prostate Cancer Variant 1: Prostate cancer follow-up. Status post radical prostatectomy. Clinical concern
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationJoint Comments on Positron Emission Tomography (NaF-18) to Identify Bone Metastasis of Cancer (CAG-00065R1)
July 2, 2009 Tamara Syrek Jensen, J.D. Acting Director, Coverage and Analysis Group Centers for Medicare & Medicaid Services 7500 Security Blvd., Mail Stop C1-09-06 Baltimore, MD 21244 Re: Joint Comments
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationClinical summary. Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT.
Clinical summary Male 30 year-old with past history of non-seminomous germ cell tumour. Presents with retroperitoneal lymphadenopathy on CT. For restaging PET/CT. PET/CT findings No significant FDG uptake
More informationPET/CT in lung cancer
PET/CT in lung cancer Andrei Šamarin North Estonia Medical Centre 3 rd Baltic Congress of Radiology 08.10.2010 Imaging in lung cancer Why do we need PET/CT? CT is routine imaging modality for staging of
More informationPage: 1 of 29. For this policy, PET scanning is discussed for the following 4 applications in oncology:
Emission Tomography Scanning Page: 1 of 29 Last Review Status/Date: June 2015 Description Positron emission tomography (PET) scans are based on the use of positron-emitting radionuclide tracers coupled
More informationColorectal Cancer and FDG PET/CT
Hybrid imaging in colorectal & esophageal cancer Emmanuel Deshayes IAEA WorkShop, November 2017 Colorectal Cancer and FDG PET/CT 1 Clinical background Cancer of the colon and rectum is one of the most
More informationNCCN Guidelines for Prostate Cancer V Web teleconference 06/17/16 and 06/30/17
Guideline Page and Request PROS-1 Submission from Myriad Genetic Laboratories, Inc. Request addition of recommendation for genetic risk assessment/testing to the Initial Clinical Assessment algorithm for
More informationCase Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.
Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule
More informationBiodistribution of Ga 68 Psma in of Patients with Prostate Normal Organs
9 ISSN:2149-455X Makale / Article Biodistribution of Ga 68 Psma in of Patients with Prostate Normal Organs Carcinoma Halil Komek 1, Hasan Morcali 2, Serdar Altindag 1, Canan Can 1, Timur Ugur 2 1 Department
More informationDisclosure. Acknowledgement. What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Rectal cancer imaging. None
What is the Best Workup for Rectal Cancer Staging: US/MRI/PET? Zhen Jane Wang, MD Assistant Professor in Residence UC SF Department of Radiology Disclosure None Acknowledgement Hueylan Chern, MD, Department
More informationPositron emission tomography (PET) in primary prostate cancer staging and risk assessment
Review Article Positron emission tomography (PET) in primary prostate cancer staging and risk assessment Sandra Bednarova 1,2, Maria L. Lindenberg 1, Maria Vinsensia 2,3, Chiara Zuiani 1, Peter L. Choyke
More informationConsensus and Controversies in Cancer of Prostate BASIS FOR FURHTER STUDIES. Luis A. Linares MD FACRO Medical Director
BASIS FOR FURHTER STUDIES Main controversies In prostate Cancer: 1-Screening 2-Management Observation Surgery Standard Laparoscopic Robotic Radiation: (no discussion on Cryosurgery-RF etc.) Standard SBRT
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationLos Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010
Los Angeles Radiological Society 62 nd Annual Midwinter Radiology Conference January 31, 2010 Self Assessment Module on Nuclear Medicine and PET/CT Case Review FDG PET/CT IN LYMPHOMA AND MELANOMA Submitted
More information